Trial of Voclosporin Meets All Primary and Secondary Endpoints with Clean Safety Profile

Landmark study reports greater success with minimally invasive vascular access procedure

NYC Surgical Associates, a leading multi-specialty surgical practice with five locations across the New York Metro area, is pioneering a unique approach to treating overactive bladders through a simple corrective procedure to relieve pressure from blood pooling in the veins surrounding the bladder, a condition that can cause urinary frequency issues. While other treatment measures such as drugs and Botox can have unwanted side effects, this minimally-invasive procedure has been shown to yield a 95% success rate with total symptom resolution.

Study in Nature Sheds New Light on Heart Treatment Controversy

Innovative external urine collection device improves quality of care and reduce facility costs

The US Pain Collaborative, comprised of advocacy leaders from across the pain community, today announced the publication of a report, titled "Chronic Pain Assessment: Patient Perspectives."

Four real-world studies presented at the Annual Liver Meeting of the American Association for the Study of Liver Diseases

The phase 3 trial (KALM-1) completion of the drug difelikefalin (CR845) shows results of improved itch-related quality of life for patients undergoing dialysis treatment

Hospitals are inherently noisy environments, with staff members discussing medical details with one another, machines beeping constantly, and the rolling of chairs or stretching across tile floors.

A large new study has found that an artery disease that mostly affects legs and feet is associated with increased use of opioids, the Society for Vascular Surgery reports.

Health communication program, supported by Amgen Oncology since 2009, has evolved with innovative tools, including virtual healthcare provider tool in English and Spanish

Analysis of more than 4,300 adverse events reveals bifurcated healthcare system challenging patient outcomes

Data from pivotal study demonstrate safety and efficacy regardless of prior gastrectomy in previously treated patients with metastatic gastric cancer (mGC) and gastroesophageal junction (GEJ) adenocarcinoma

Data from Prospective, Observational Study will Strengthen Clinical Evidence and Support Continued Cologuard Adoption

New Study Shows Brainomix's Unique AI-Driven Software Gives Doctors Reliable Information to Treat Stroke Patients from Universally Available Imaging Systems

App Will Empower Breast Implant Patients by Providing a Digital Wallet with Their Implant Record and Serve as a Two-Way Doctor-Patient Communications Tool

In stark contrast to Democrats who seek to push all Americans into socialized medicine, an Executive Order signed on October 3 by President Donald Trump takes bold steps toward increasing the ability of American seniors to choose the medical care and insurance options best for them, instead of being trapped within increasingly insolvent government-run programs.

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA), an immuno-oncology company focused on innovative treatments based on the Company's patent pending TriKE™ technology, announced today that Tim Schacker, M.D., Jeffrey S. Miller, M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg discussing their design of an HIV-TriKE™ containing an antigen binding fragment (Fab) from a broadly-neutralizing antibody targeting the HIV-Env protein.

Study met both co-primary endpoints with high statistical significance, demonstrating autograft sparing and durable wound closure at three months with StrataGraft

Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its biopharmaceutical business as EMD Serono in the US and Canada, today announced that new data representing several key therapeutic agents from its diverse oncology pipeline will be presented at the 2019 European Society for Medical Oncology (ESMO) Congress, September 27–October 1, in Barcelona, Spain.